Lenzilumab (anti-GM-CSF)

GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, et al. Blood. 2013;121(25):5068-5077.


Disclaimer: The information contained in the listed publications concerns biologics that are under pre-clinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.